Resumen de: WO2019210189A1

Provided are compositions and methods for using the same. In some embodiments, the compositions include an EPELN encapsulating and/or having associated therewith an active agent and a plasma membrane derived from a tumor and/or cancer cell coating the EPELN. In some embodiments, the active agent is a therapeutic agent or an immune response modifier, and in some embodiments the plasma membrane has one or more tumor- associated and/or cancer-associated antigens. Also provided are methods for using the compositions for treating tumors and/or cancers, inducing anti-tumor and/or anti-cancer immune responses, activating antigen-presenting cells, targeting CD1 lc dendritic cells, and preventing or reducing metastasis.

Resumen de: WO2019210296A1

A muitivesicular liposome composition includes a plurality of multi vesicular liposomes. Each multi vesicular liposome includes a carrier liposome particle including carrier phospholipid bilayer and having an average diameter less than 1 micron; and at least one sub-chamber liposome nanoparticle including a sub-chamber liposome nanoparticle bilayer and having an average diameter less than about 50 nm. The carrier liposome particle encapsulates the at least one sub-chamber liposome nanoparticle. Characteristically, tail groups of the carrier liposome phospholipids are larger than tail groups phospholipids of the at least one sub-chamber liposome nanoparticle.

Resumen de: WO2019207060A1

The invention provides a composition which is suitable for the delivery of RNA, which composition comprises (i) particles contained in a liquid phase, wherein the particles comprise RNA and a lipid composition, and (ii) 1,2 propanediol. The lipid composition comprises (i-a) a cholesterol derivative, (i-b) a phosphoglyceride, and (i-c) a pegylated phosphoglyceride. Further provided are a method for preparing the composition, and a solid composition which is obtainable by freezing the composition wherein particles are contained in a liquid phase.

Resumen de: WO2019209825A1

The present disclosure describes a novel sustained-release formulation for the local delivery of CDK9 inhibitors.

Resumen de: WO2019204666A1

Provided nucleic acid- based expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, within a target cell, including a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell. Also provided are formulations and systems, including fusogenic lipid nanoparticle (LNP) formulations and systems, for the delivery of nucleic acid-based expression constructs as well as methods for making and using such nucleic acid-based expression constructs, formulations, and systems for reducing, preventing, and/or eliminating the growth and/or survival of a cell, such as a senescent cell and/or a cancer cell, which is associated with aging, disease, or other condition as well as methods for the treatment of aging, disease, or other conditions by the in vivo administration of a formulation, such as a fusogenic LPN formulation, comprising an expression construct for the target cell-specific, production of a therapeutic protein, such as a pro-apoptotic protein, in a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell.

Resumen de: WO2019204869A1

The present invention relates to improved prodrugs, and compositions thereof. In particular, it relates to amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid crystalline nanostructured nanoparticles, and uses thereof to treat animals, including humans.

Resumen de: WO2021034850A1

The present invention provides aqueous in-situ gel ophthalmic formulations, each including water, difluprednate and a biocompatible polysaccharide, wherein a gel is formed in situ at physiological temperature with instant viscosity increase upon instillation of the formulation into an eye. In the formulations, nanocarriers may be formed by a surfactant or solubilizer contained in the formulation, with or encapsulating difluprednate, and the nanocarriers have an average particle size of 10 to 500 nm or 10 to 150 nm or 10-to 50 nm..

Resumen de: WO2021033095A1

Disclosed is a method for making and using insoluble, biodegradable, nanoparticles containing the omega-3 fatty acids EPA and DHA in selected ratios. Tests show a surprising effect that the nanoformulation is twice as potent and at least five times more sustained leading to at least tenfold (2x5) higher bioavailability at equal dose (1% v/v).

Resumen de: WO2021034289A1

The invention is related to targeting the non small cell lung cancer adenocarcinoma via the pathway mediated with the cannabinoid receptor for the first time with the synthetic cannabinoid agonist arachidonoyl cyclopropylamide (ACPA). An ACPA-PCL nanoparticle release system has been developed that is based on nanoengineering which provides long term controlled release and stability of the CB1 receptor agonist ACPA following the determination of the efficient dose and the antiproliferative effect of ACPA on non small cell lung cancer lines, that are known to express the cannabinoid (CB) receptors, in in vitro medium at different doses.

Resumen de: WO2021034281A1

The present invention relates to a method for producing a bioactive component-containing nanocomposite, specifically a method for producing a montmorillonite-based, bioactive component-containing nanocomposite, as well as to a montmorillonite-based nanocomposite containing a bioactive component, particularly curcumin or dexketoprofen.

Resumen de: WO2021031839A1

Provide are a targeted polypeptide-modified drug-loaded lipoprotein nano-drug delivery system, and preparation and application thereof. The drug delivery system comprises a lipid, an apolipoprotein, a loaded drug, and a targeted polypeptide, and the targeted polypeptide is formed by covalently linking, by a bridge structure, a nanocarrier linking end and a peptide chain which activates a macropinocytosis function. The drug delivery system modified by a polypeptide actively targets and can effectively regulate a variety of tumor stem cells; the use of the lipoprotein nano-drug delivery system in combination with mediation of enhanced macropinocytosis mechanism achieves pinocytosis of more lipoprotein nano-drugs by tumor stem cells, and targeted regulation of tumor stem cells in vivo and in vitro can be implemented safely and effectively with a lower dosage. The nano-drug delivery system can be applied to prevention or treatment of a variety of tumors or central nervous system diseases, and has a simple and safe preparation process, and good research value and clinical application prospects.

Resumen de: WO2021030913A1

The present disclosure relates to cannabinoid compositions that are rehydratable and that upon such rehydration retain at least some of the properties of the original cannabinoid emulsions from which the cannabinoid composition was obtained. In particular, to cannabinoid compositions formed by spray drying of an emulsion, the composition comprising at least one cannabinoid, a carrier oil, one or more emulsifiers, and a sugar carrier, where the composition has a water activity that is less than about 0.5. The emulsion may include a nanoemulsion, a microemulsion, or both a nanoemulsion and a microemulsion. The present disclosure also relates to method of manufacturing same.

Resumen de: WO2021032894A1

Provided herein is a composition comprising nanoparticles, wherein the nanoparticles comprise chitosan or a derivative thereof and clathrin or a derivative thereof. The chitosan or derivative thereof may be conjugated to clathrin or a derivative thereof. Also provided are pharmaceutical compositions comprising nanoparticles, and therapeutic uses thereof for delivering active agents across the blood- brain-barrier and treating neurological disease. Methods of producing compositions comprising nanoparticles are also described.

Resumen de: WO2021034334A1

The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl -cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.

Resumen de: WO2021031321A1

A multi-color up-conversion nanoprobe, a preparation method therefor, and an application thereof. The nanoprobe comprises up-conversion nano particles and a silicon dioxide layer sequentially from inside to outside. The up-conversion nanoparticles comprise a NaYF 4 core and a NaYF 4 shell. A NaYF 4 intermediate luminescent layer is arranged between the NaYF 4 core and the NaYF 4 shell. The NaYF 4 intermediate luminescent layer is doped with Y 3+, Yb 3+, Tm 3+, and Ho 3+. A plurality of photosensitizers are doped between the up-conversion nanoparticles and the silica layer and/or in the silica layer. The thickness of the silica layer is less than 15 nm, and the outer surface of the silica layer is modified with a mitochondrial targeting ligand. The plurality of photosensitizers comprises at least three photosensitizers, one of which is indocyanine green. The prepared UCNPs-based nanoprobe can be used to carry out PDT treatment on deep tumors.

Resumen de: US2021052646A1

The present invention also provides a CAR- or exogenous TCR-zo expressing immunocyte obtained by introducing the lipid nanoparticle into in vivo or ex vivo T cells, and an in vivo or ex vivo therapeutic approach using the immunocytes for disease such as cancer and the like.

Resumen de: US2021052607A1

The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.

Resumen de: US2021052637A1

The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

Resumen de: US2021052909A1

The present invention provides methods and compositions for the remote control of cell function based on the use of a magnetic field to excite paramagnetic nanoparticles targeted to specific cell types. The cell type of interest expresses an ion channel wherein excitation of the paramagnetic nanoparticles results in a physical change that is transduced into a cellular response. Such cellular responses may include, for example, increases in gene expression resulting in production of one or more physiologically active proteins. The expression of such proteins can be used to treat a variety of different inherited or acquired diseases or disorders in a subject.

Resumen de: US2021052750A1

The current inventive technology includes system, methods and compositions for the generation of a cloaked microbubble having buried-ligand architecture (BLA) that may allow the cloaked microbubble to circumvent potentially deleterious immunogenic, or other unwanted chemical responses in a host. The current inventive technology may also includes systems and methods to isolate monodisperse size populations of microbubbles for enhanced therapeutic and diagnostic applications.

Resumen de: US2021052731A1

Provided are nanoparticles surface functionalized with PEG groups and having one or more photosensitizer group. The PEG groups may be functionalized. The nanoparticles may also include therapeutic groups and/or targeting groups. The nanoparticles may be made by hydrolysis of a silica precursor and, optionally, an alumina precursor, in various aqueous reaction mediums. The nanoparticles may be used in photodynamic therapy methods. The methods may also include imaging of an individual.

Resumen de: US2021052638A1

This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. The continuous process causes at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s). Results include constituents formed in the liquid including micron-sized particles and/or nanoparticles (e.g., metallic-based nanoparticles) of novel size, shape, composition, zeta potential and properties present in a liquid.

Resumen de: US2021052616A1

The invention relates to a new form of a drug in the form of anthracycline encapsulated with a polysaccharide selected from epirubicin, daunorubicin, doxorubicin, idarubicin, especially encapsulated with dextran, for use in the treatment of specific tumours.

Resumen de: US2021054106A1

The present invention relates to modified polysaccharide-based self-assembled aggregates capable to encapsulate and deliver active agents into and between media of different hydrophilicity/hydrophobicity.

Resumen de: US2021052508A1

Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.